Brokerage firm Stifel Nicolaus Maintains its rating on Cara Therapeutics Inc(NASDAQ:CARA). In a research note issued to the investors, the brokerage major Lowers the price-target to $24.00 per share. The shares have been rated Buy. The rating by Stifel Nicolaus was issued on Aug 5, 2016.
Cara Therapeutics Inc (CARA) shares turned negative on Wednesdays trading session with the shares closing down -0.27 points or -4.29% at a volume of 5,20,497. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $6.3. The peak price level was also seen at $6.3 while the days lowest was $5.97. Finally the shares closed at $6.02. The 52-week high of the shares is $22.35 while the 52-week low is $4.26. According to the latest information available, the market cap of the company is $164 M.
Cara Therapeutics Inc(CARA) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $79.00K. Analysts had an estimated revenue of $130.00K. Earnings per share were $-0.48. Analysts had estimated an EPS of $-0.42.
Several Insider Transactions has been reported to the SEC. On Apr 20, 2016, Frederique Ph.d. Menzaghi (VP-Research & Development) sold 6,000 shares at $9.00 per share price.Also, On Jan 27, 2016, Michael E Lewis (Chief Scientific Advisor) sold 7,262 shares at $10.93 per share price.On Jan 12, 2016, Dean Slagel (director) sold 44,000 shares at $17.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Cara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes with no off-target activities.